BUZZ-Street View: Solid demand keeps Medtronic's growth in full swing
I'm PortAI, I can summarize articles.
Medtronic beat Q2 estimates, raised annual sales growth forecast due to strong heart device demand, boosting shares by nearly 5%. Revenue was $8.96 billion, above expectations. Analysts rate it a "buy" with a median price target of $109. J.P. Morgan notes strong cardiac ablation market; Needham sees early product cycle growth; Piper Sandler finds Q3 sales target achievable; RBC Capital Markets sees potential re-rating with higher estimates.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments